Hypersensitivity Pneumonitis Induced by Hexamethylene Diisocyanate.
نویسندگان
چکیده
منابع مشابه
å¡ CASE REPORT å¡ Hypersensitivity Pneumonitis Induced by Hexamethylene Diisocyanate
A case of hypersensitivity pneumonitis (HP) induced by hexamethylene diisocyanate (HDI) is described. Serial determinations of the lymphocyte surface phenotypes by two-color assay revealed the following: 1) increased activated cytotoxic T lymphocytes in the bronchoalveolar lavage fluid (BALF), and 2) increased percentage and absolute number of non-major histo compatibility complex (MHC)-restric...
متن کاملHypersensitivity pneumonitis induced by trimethoprim.
intracranial course. The sixth nerve occupies a superficial position in relation to the fourth ventricle, which communicates directly through the foramina of Magendie and Luschka with the subarachnoid space. Dye studies have shown that agents introduced into the spinal canal frequently reach the medulla, which may explain the peculiar affinity of the sixth nerve to palsy.4 The contrast agents i...
متن کاملHaemorrhagic hypersensitivity pneumonitis due to naphthylene-1,5-diisocyanate.
Symptoms of hypersensitivity pneumonitis and massive pulmonary haemorrhage occurred in a 24-yr-old male shortly after occupational exposure to naphthylene-1,5-diisocyanate (NDI). The present examination was performed approximately 1-yr after the initial life-threatening haemoptysis and following an uneventful recovery after resection of the middle lobe, which had been identified bronchoscopical...
متن کاملLenalidomide-induced hypersensitivity pneumonitis.
symptoms recovered within few days. The transbronchial biopsies in the patients described by Lerch et al. [1] and Thornburg et al. [2] revealed a nonspecific, hypersensitivity pneumonitis (compatible with toxic drug-induced damage). Immunosuppressive therapy with steroids induced a rapid relief of all symptoms in all 3 cases. Infectious cause of the pulmonary infiltrates could be excluded by br...
متن کاملRituximab-induced hypersensitivity pneumonitis.
Rituximab is a chimeric anti-CD20 monoclonal antibody used to treat CD20+ non-Hodgkin's lymphoma. Although pulmonary adverse reactions such as cough, rhinitis, bronchospasm, dyspnea and sinusitis are relatively common, other respiratory conditions like cryptogenic organizing pneumonia, interstitial pneumonitis and diffuse alveolar hemorrhage have rarely been reported. Only 2 possible cases of r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Internal Medicine
سال: 1992
ISSN: 0918-2918,1349-7235
DOI: 10.2169/internalmedicine.31.912